Nina Cosdon

The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.

Older adults with comorbidities, including diabetes and chronic heart and lung disease, are at an increased risk of RSV hospitalization and death.

Why has this season brought an unprecedented number of severe RSV infections, and why is vaccine development taking so long?

RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.

In a recent clinical trial, Evusheld recipients at increased risk of severe COVID-19 infection saw a 77% reduced risk of developing COVID-19.

C difficile was found on 45% of shoe soles and 26.2% of private residences.